SLC5A2 and heart failure: In addition, when SGLT-2 inhibitors were compared to sulphonylureas, they more efficiently reduced the major adverse cardiovascular event (−1.59; −3.17, 0.23) and hospitalization for heart failure (−0.64; −1.25, 0.18) [107].